Medicines Co /de (MDCO) Files Form 4 Insider Buying : Christopher T Cox Buys 53,340 Shares

Medicines Co /de (MDCO): Christopher T Cox , EVP & Chief Corp. Dev. Officer of Medicines Co /de purchased 53,340 shares on Jun 7, 2016. The Insider buying transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were purchased at $37.50 per share for a total value of $2,002,944.38 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Robert G. Savage (director) sold 10,000 shares at $36.95 per share price.On May 26, 2016, Melvin K Spigelman (director) sold 15,000 shares at $37.00 per share price.Also, On May 18, 2016, William Crouse (director) sold 15,000 shares at $35.15 per share price.On May 18, 2016, Clive Meanwell (CEO) sold 10,000 shares at $35.00 per share price.

The Medicines Company: On Tuesday, Jun 7, 2016 heightened volatility was witnessed in The Medicines Company which led to swings in the share price. The shares opened for trading at $37.04 and hit $38.45 on the upside , eventually ending the session at $38.07, with a gain of 3.00% or 1.11 points. The heightened volatility saw the trading volume jump to 56,75,838 shares. The 52-week high of the share price is $43.79 and the company has a market cap of $2,668 M . The 52-week low of the share price is at $25.38.

The Medicines Company Money Flow Index Chart

Company has been under the radar of several Street Analysts.The Medicines Company is Reiterated by Chardan Capital Markets to Buy and the brokerage firm has raised the Price Target to $ 65 from a previous price target of $50 .The Rating was issued on Mar 21, 2016.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products are: Angiomax (bivalirudin) Cleviprex (clevidipine) injectable emulsion Minocin (minocycline) for injection Orbactiv (oritavancin) PreveLeak and Recothrom Thrombin topical (Recombinant). The Company’s products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States cangrelor IONSYS (fentanyl iontophoretic transdermal system) Raplixa formerly referred to as Fibrocaps and RPX-602. The Company’s four research and development product candidates include ABP-700 ALN-PCSsc Carbavance and MDCO-216. The Company also develops ABP-700 an intravenous anesthetic which is in Phase I of clinical studies.

Leave a Reply

The Medicines Company - Is it time to Sell?

Top Brokerage Firms are advising their investors on The Medicines Company. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.